Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated H5N1 whole-virion influenza vaccine
- Development stage
- Unknown
- Lead developer
- Jilin Yatai Biological Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The inactivated H5N1 whole-virion influenza vaccine is a viral vaccine developed for the prevention of avian influenza caused by the H5N1 subtype of the Influenza A virus. This specific formulation, developed by Jilin Yatai Biological Pharmaceutical, is produced using Vero cell culture technology rather than traditional egg-based methods. The vaccine contains the entire inactivated virus, which presents a broad array of viral antigens, including hemagglutinin (HA) and neuraminidase (NA), to the host immune system to stimulate protective antibody and cellular immune responses. It has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, and preliminary immunogenicity in healthy adults.
- Other names
- inactivated H5N1 whole-virion vaccine (Vero cell)H5N1 whole-virion vaccineH-5N1 whole-virion vaccineH 5N1 whole-virion vaccine
02
Targets
N1 NA (Influenza A neuraminidase N1)NP (Taï Forest ebolavirus nucleoprotein)RdRp (Influenza A virus RNA-directed RNA polymerase complex)M1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on inactivated H5N1 whole-virion influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated H5N1 whole-virion influenza vaccine.